Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology December 1, 2024 Charalampos Brakatselos, Alexia Polissidis, George Ntoulas et al. 10 citations
Repeated administration of ketamine (KET) has been used to model schizophrenia-like symptomatology in rodents, but the psychotomimetic neurobiological and neuroanatomical underpinnings remain elusive. In parallel, the unmet need for a better treatment of schizophrenia requires the development of novel therapeutic strategies. Cannabidiol (CBD), a major non-addictive phytocannabinoid has been...